Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 19.05% is 29% above its 5-year average of 14.79%, around the middle of its 5-year range (-16.26%–52.22%).
37.99% above its 12-month average of 13.81%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 9.81%.
EBITDA MARGIN
19.05%
EBITDA MARGIN AVG TTM
13.81%
EBITDA MARGIN AVG 3Y
22.14%
EBITDA MARGIN AVG 5Y
14.79%
EBITDA MARGIN AVG 10Y
1.40%
EBITDA MARGIN AVG 15Y
1.98%
EBITDA MARGIN AVG 20Y
0.95%
CURRENT VS TTM AVG
+37.99%
CURRENT VS 3Y AVG
-13.97%
CURRENT VS 5Y AVG
+28.77%
CURRENT VS 10Y AVG
+1260.93%
CURRENT VS 15Y AVG
+861.31%
CURRENT VS 20Y AVG
+1901.11%
Market Cap
$6.65B
EBITDA Margin
15.93%
TTM Avg
16.80%
3Y Avg
17.55%
5Y Avg
18.41%
Market Cap
$7.29B
EBITDA Margin
-38.32%
TTM Avg
-51.29%
3Y Avg
-52.67%
5Y Avg
-38.88%
Market Cap
$6.52B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$6.51B
EBITDA Margin
24.71%
TTM Avg
29.36%
3Y Avg
25.12%
5Y Avg
17.03%
Market Cap
$6.48B
EBITDA Margin
21.42%
TTM Avg
19.40%
3Y Avg
15.87%
5Y Avg
16.39%
Market Cap
$7.57B
EBITDA Margin
-92.07%
TTM Avg
-49.82%
3Y Avg
-47.83%
5Y Avg
-47.83%
Market Cap
$7.58B
EBITDA Margin
-684.44%
TTM Avg
-1767.79%
3Y Avg
-2575.30%
5Y Avg
-1786.18%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alkermes plc (ALKS) | $6.97B | 19.05% | 13.81% | 22.14% | 14.79% |
| Chemed Corporation (CHE)vs › | $6.65B | 15.93% | 16.80% | 17.55% | 18.41% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.29B | -38.32% | -51.29% | -52.67% | -38.88% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.52B | 6.82% | 6.08% | -0.44% | -8.67% |
| Immunovant, Inc. (IMVT)vs › | $6.51B | N/A | N/A | N/A | N/A |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 24.71% | 29.36% | 25.12% | 17.03% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.48B | 21.42% | 19.40% | 15.87% | 16.39% |
| Hinge Health, Inc. (HNGE)vs › | $7.57B | -92.07% | -49.82% | -47.83% | -47.83% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.58B | -684.44% | -1767.79% | -2575.30% | -1786.18% |
| HealthEquity, Inc. (HQY)vs › | $7.60B | 36.33% | 34.52% | 30.06% | 28.41% |
Gross Margin
84.6%
EBITDA Margin
19.1%
Operating Margin
17.2%
Net Margin
4.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 9.81% |
| 2026-03-31 | -7.34% |
| 2025-12-31 | 16.11% |
| 2025-09-30 | 24.65% |
| 2025-06-30 | 25.80% |
| 2025-03-31 | 6.92% |
| 2024-12-31 | 39.43% |
| 2024-09-30 | 29.55% |
| 2024-06-30 | 29.20% |
| 2024-03-31 | 14.66% |
| 2023-12-31 | 52.22% |
| 2023-09-30 | 28.31% |
| 2023-06-30 | 48.64% |
| 2023-03-31 | 2.69% |
| 2022-12-31 | -0.30% |
| 2022-09-30 | -16.26% |
| 2022-06-30 | -5.45% |
| 2022-03-31 | -2.65% |
| 2021-12-31 | 7.25% |
| 2021-09-30 | -0.09% |
| 2021-06-30 | 7.54% |
| 2021-03-31 | 1.28% |
| 2020-12-31 | -3.71% |
| 2020-09-30 | 3.74% |
| 2020-06-30 | -5.38% |
| 2020-03-31 | -6.81% |
| 2019-12-31 | 2.56% |
| 2019-09-30 | -13.04% |
| 2019-06-30 | -5.72% |
| 2019-03-31 | -25.26% |
| 2018-12-31 | 8.21% |
| 2018-09-30 | -4.38% |
| 2018-06-30 | 8.43% |
| 2018-03-31 | -16.06% |
| 2017-12-31 | 11.28% |
| 2017-09-30 | -6.13% |
| 2017-06-30 | -9.14% |
| 2017-03-31 | -24.56% |
| 2016-12-31 | 0.52% |
| 2016-09-30 | -20.70% |
| 2016-06-30 | -12.31% |
| 2016-03-31 | -34.56% |
| 2015-12-31 | -27.76% |
| 2015-09-30 | -37.15% |
| 2015-06-30 | -21.07% |
| 2015-03-31 | -2.99% |
| 2014-12-31 | 5.53% |
| 2014-09-30 | -4.69% |
| 2014-06-30 | 1.37% |
| 2014-03-31 | 5.11% |
| 2013-09-30 | 14.16% |
| 2013-06-30 | 26.87% |
| 2013-03-31 | 22.83% |
| 2012-12-31 | 32.27% |
| 2012-09-30 | 19.55% |
| 2012-06-30 | 32.95% |
| 2012-03-31 | 6.72% |
| 2011-12-31 | 12.66% |
| 2011-09-30 | -10.13% |
| 2011-06-30 | -19.35% |
| 2011-03-31 | -21.82% |
| 2010-12-31 | -22.20% |
| 2010-09-30 | -10.31% |
| 2010-06-30 | -25.98% |
| 2010-03-31 | -35.97% |
| 2009-12-31 | -3.18% |
| 2009-09-30 | -5.59% |
| 2009-06-30 | -0.16% |
| 2009-03-31 | -23.95% |
| 2008-12-31 | 74.19% |
| 2008-09-30 | 13.18% |
| 2008-06-30 | 42.51% |
| 2008-03-31 | -24.05% |
| 2007-12-31 | 1.76% |
| 2007-09-30 | 16.66% |
| 2007-06-30 | 19.88% |
| 2007-03-31 | 11.39% |
| 2006-12-31 | 9.97% |
| 2006-09-30 | 11.11% |
| 2006-06-30 | 5.11% |
| 2006-03-31 | 17.85% |
| 2005-12-31 | 14.92% |
| 2005-09-30 | 35.24% |
| 2005-06-30 | -30.90% |
| 2005-03-31 | -43.77% |
| 2004-12-31 | -24.19% |
| 2004-09-30 | -65.57% |
| 2004-06-30 | -295.40% |
| 2004-03-31 | -133.91% |
| 2003-12-31 | -156.72% |
| 2003-09-30 | -316.50% |
| 2003-06-30 | -541.36% |
| 2003-03-31 | -133.94% |
| 2002-12-31 | -71.69% |
| 2002-09-30 | -290.49% |
